The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibody Share News (FAB)

Share Price Information for Fusion Antibody (FAB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.40
Bid: 3.30
Ask: 3.50
Change: 0.00 (0.00%)
Spread: 0.20 (6.061%)
Open: 3.40
High: 3.40
Low: 3.40
Prev. Close: 3.40
FAB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Beeks Financial Cloud is ahead of expectations

Tue, 06th Feb 2024 10:05

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Beeks Financial Cloud Group PLC, up 34% at 145.00 pence, 12-month range 81.42p-155.00p. The cloud computing and connectivity provider says it has won a number of competitive tenders in the first half of financial 2024, and now expects trading in financial 2025 to be "significantly" ahead of previous board expectations. Beeks notes that it has signed a USD2.3 million Proximity Cloud expansion contract, as well as a conditional contract with "one of the largest exchange groups globally." Chief Executive Gordon McArthur says: "We continue to progress with the execution of our 'land and expand' strategy, quickly demonstrating the value of our offerings, as evidenced by the significant Proximity Cloud expansion contract announced this morning and the winning of a third major global exchange customer for our Exchange Cloud offering. We see considerable expansion potential across our customers, as they migrate increasing proportions of their trading infrastructure to the cloud."

----------

Fusion Antibodies PLC, up 16% at 5.50p, 12-month range 3.02p-56.00p. Shares in the contract researcher rise. It receives a follow-on project under a collaborative research and development agreement with an unnamed "US-based biotechnology company". The follow on project is worth USD650,000. CEO Adrian Kinkaid says: "It is always thrilling and satisfying to share in our clients' successes. We are delighted that the programme has been so productive, and we look forward to continuing to work with our client to bring better antibodies to the clinic more rapidly. The collaborative nature of the project, with creative problem solving from both parties over the full length of the programme, makes this a model example of Fusion's Integrated Therapeutic Antibody Service and highlights the strong reputation that Fusion has for delivering high quality therapeutic antibodies."

----------

AIM - LOSERS

----------

PCI-PAL PLC, down 10% at 49.98p, 12-month range 38.25p-66.70p. Shares in the provider of cloud-based secure payment solutions for business communications fall despite a positive trading update. Revenue in the six months to December 31 rises 20% to GBP8.7 million from GBP7.3 million a year before. Annual recurring revenue in the period increases 23% to GBP14.7 million from GBP11.9 million. Looking ahead, CEO James Barham says: "The start of H2 has seen the group maintain new sales momentum and we continue to focus on delivering the group's profitability objectives, enhancing shareholder value, and capitalising on the strategic opportunities for continued growth."

----------

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
30 Mar 2020 16:52

Fusion Antibodies Trading In Line With Expectations Amid Outbreak

Fusion Antibodies Trading In Line With Expectations Amid Outbreak

Read more
17 Mar 2020 15:54

DIRECTOR DEALINGS SUMMARY: IWG And Man Chiefs Buy GBP3 Million Worth

DIRECTOR DEALINGS SUMMARY: IWG And Man Chiefs Buy GBP3 Million Worth

Read more
3 Feb 2020 17:32

DIRECTOR DEALINGS SUMMARY: TalkTalk Telecom Boss Buys GBP200,000 Worth

DIRECTOR DEALINGS SUMMARY: TalkTalk Telecom Boss Buys GBP200,000 Worth

Read more
29 Jan 2020 13:35

Fusion Antibodies Expects Annual Revenue Rise Ahead Of Expectations

Fusion Antibodies Expects Annual Revenue Rise Ahead Of Expectations

Read more
29 Jan 2020 09:32

Fusion Antibodies sees 'favourable trends' continue in H2

(Sharecast News) - Pre-clinical therapeutic drug and diagnostics firm Fusion Antibodies said on Wednesday that trading in the third quarter of the financial year had continued the "favourable trends" experienced in the first half.

Read more
10 Jan 2020 12:09

DIRECTOR DEALINGS: Fusion Antibodies Non-Executive Mawson Buys Shares

DIRECTOR DEALINGS: Fusion Antibodies Non-Executive Mawson Buys Shares

Read more
3 Dec 2019 18:08

DIRECTOR DEALINGS: Fusion Antibodies Non-Exec Mawson Buys Shares

DIRECTOR DEALINGS: Fusion Antibodies Non-Exec Mawson Buys Shares

Read more
2 Dec 2019 11:27

Fusion Antibodies cuts losses after revenue leaps

(Sharecast News) - Fusion Antibodies on Monday reported a narrowed loss after revenue more than doubled following the launch of its RAMP service.

Read more
2 Dec 2019 10:49

Fusion Antibodies Revenue Takes Off But Order Visibility Cloudy

Fusion Antibodies Revenue Takes Off But Order Visibility Cloudy

Read more
22 Oct 2019 15:13

Fusion Antibodies pleased with progress in first half

(Sharecast News) - Preclinical antibody discovery company Fusion Antibodies updated the market on the six months ended 30 September on Tuesday, reporting continued revenue growth amid the commercial roll out of new services.

Read more
22 Oct 2019 14:31

Fusion Antibodies Predicts Rise In Interim Revenue And Orders

Fusion Antibodies Predicts Rise In Interim Revenue And Orders

Read more
3 Jul 2019 17:03

DIRECTOR DEALINGS: Fusion Antibodies CEO, Non-Executives Buy Shares

(Alliance News) - Fusion Antibodies PLC said Wednesday that its Chief Executive Officer and two Non-Executive Directors have bought around GBP31,794 in shares in the company in deals on Executive

Read more
2 Jul 2019 10:46

Fusion Antibodies Annual Loss Widens After Rocky First Half

(Alliance News) - Fusion Antibodies PLC on Tuesday said its loss gapped wider after a weak first half brought annual revenue down 19%, though this was followed by a much stronger second antibody a

Read more
17 Apr 2019 11:49

Fusion Antibodies Annual Revenue Declines On Weak First Half

LONDON (Alliance News) - Fusion Antibodies PLC on Wednesday reported an improved performance in the second half of its recently ended financial year after "disappointing" first company a

Read more
17 Apr 2019 10:46

Fusion Antibodies revenues soar in strong second half

(Sharecast News) - Pharmaceutical research outfit Fusion Antibodies reported a strong second half on Wednesday, driven by a significant increase in orders.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.